Immunohistochemical and immunochemical study of amyloid in liver affected by systemic Aλ amyloidosis with antibodies against three different regions of immunoglobulin λ light chain

Pathology International

Volumn 57, Issue 6, 2007, Pages 343-350

  Kiyama, Makiko ^a   Hoshii, Yoshinobu ^a   Cui, Dan ^a   Kawano, Hiroo ^a   Kanda, Takashi ^a   Ishihara, Tokuhiro ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AL amyloidosis; Immunoglobulin light chain; Immunohistochemistry; Liver

Indexed keywords

AMYLOID; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ARTICLE; CONTROLLED STUDY; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER DISEASE; PORTAL VEIN; PRIORITY JOURNAL; WESTERN BLOTTING;

AMYLOID; AMYLOIDOSIS; ANTIBODIES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LIVER; LIVER DISEASES;

EID: 34249802084     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2007.02106.x     Document Type: Article

References (26)

1. Westermark P, Benson MD, Buxbaum JN et al. Amyloid: Toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005 12 : 1 4.
2. Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005 79 : 319 28.
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995 32 : 45 59.
4. Kaplan B, Martin BM, Livneh A, Pras M, Gallo GR. Biochemical subtyping of amyloid in formalin-fixed tissue samples confirms and supplements immunohistologic data. Am J Clin Pathol 2004 121 : 794 800.
5. Buxbaum J. Mechanisms of disease: Monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 1992 6 : 323 46.
6. Röcken C, Hegenbarth V, Schmitz M et al. Plasmacytoma of the tonsil with AL amyloidosis: Evidence of post-fibrillogenic proteolysis of the fibril protein. Virchows Arch 2000 436 : 336 44.
7. Picken MM, Gallo G, Buxbaum J, Frangione B. Characterization of renal amyloid derived from the variable region of the lambda light chain subgroup II. Am J Pathol 1986 124 : 82 7.
8. Hoshii Y, Setoguchi M, Iwata T et al. Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 2001 51 : 264 70.
9. Isersky C, Ein D, Page DL, Harada M, Glenner GG. Immunochemical cross-reactions of human amyloid proteins with human immunoglobulin light polypeptide chains. J Immunol 1972 108 : 486 93.
10. Imada N. Pathological study on amyloidosis. Isolation and purification of amyloid fibril protein and biochemical and immunological analysis. Yamaguchi Med J 1981 30 : 149 62 (in Japanese).
11. Iwata T, Hoshii Y, Kawano H et al. Hepatic amyloidosis in Japan: Histological and morphometric analysis based on amyloid proteins. Hum Pathol 1995 26 : 1148 53.
12. Wikler M, Titani K, Shinoda T, Putnam FW. The complete amino acid sequence of a lambda type Bence-Jones protein. J Biol Chem 1967 242 : 1668 70.
13. Sletten K, Natvig JB, Husby G, Juul J. The complete amino acid sequence of a prototype immunoglobulin-lambda light-chain-type amyloid-fibril protein AR. Biochem J 1981 195 : 561 72.
14. Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 1987 57 : 230 36.
15. Pras M, Schubert M, Zucker-Franklin D, Rimon A, Franklin EC. The characterization of soluble amyloid prepared in water. J Clin Invest 1968 47 : 924 33.
16. Kisilevsky R. The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000. Amyloid 2000 7 : 23 5.
17. Roskams T, Moshage H, De Vos R, Guido D, Yap P, Desmet V. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995 21 : 950 58.
18. Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom's macroglobulinemia. Clin Immunol Immunopathol 1994 71 : 183 9.
19. Solomon A, Weiss DT. Serologically defined V region subgroups of human lambda light chains. J Immunol 1987 139 : 824 30.
20. Infante AJ, Putnam FW. Primary structure of a human IgA1 immunoglobulin. V. Amino acid sequence of a human IgA lambda light chain (Bur). J Biol Chem 1979 254 : 9006 16.
21. Glenner GG. Amyloid deposits and amyloidosis. The beta fibrilloses (first of two parts). N Engl J Med 1980 302 : 1283 92.
22. Solomon A. Light chains of immunoglobulins: Structural-genetic correlates. Blood 1986 68 : 603 10.
23. Engvig JP, Olsen KE, Gislefoss RE, Sletten K, Wahlstrom O, Westermark P. Constant region of a kappa III immunoglobulin light chain as a major AL-amyloid protein. Scand J Immunol 1998 48 : 92 8.
24. Solomon A, Weiss DT, Murphy CL, Hrncic R, Wall JS, Schell M. Light chain-associated amyloid deposits comprised of a novel kappa constant domain. Proc Natl Acad Sci USA 1998 95 : 9547 51.
25. Wally J, Kica G, Zhang Y et al. Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain. Biochim Biophys Acta 1999 1454 : 49 56.
26. Olsen KE, Sletten K, Westermark P. Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins. Biochem Biophys Res Commun 1998 251 : 642 7.